Insights from Phase 2a Development of a Novel Immune-Modulating Therapy in IPF on Translating Mechanism into Meaningful Clinical Signals
- What early clinical and molecular signals tell us about targeting upstream immune pathways, including how gene expression, serum biomarkers, and immune modulation can demonstrate impact on core drivers of fibrosis such as myofibroblast activation, ECM deposition, and epithelial injury
- Evaluating evidence for fibrosis resolution and lung repair, including signals of basement membrane restoration and epithelial cell transition, and how these reshape expectations for what ‘efficacy’ looks like in IPF trials
- Positioning novel therapies in an evolving treatment landscape, including where immune-modulating and regenerative approaches may sit alongside existing antifibrotics, and what differentiation is required to support combination strategies and future standard-of-care integration